Astellas is a global pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products, especially in areas where there is a high degree of unmet medical need. Astellas is different not only because of what they do, but how they do it. Every employee across the globe is grounded in an unwavering commitment to keep the patient at the center of everything they do and a strong culture of diversity, inclusion, and integrity. Based in Japan, Astellas has 16,600 employees worldwide, and its Americas and R&D headquarters in Northbrook, Illinois.
Astellas has remained at the forefront of change by continuing to deliver innovative science and solutions to address the unmet needs of the patients they serve. The company’s pipeline currently has 31 investigational compounds in Phase II or beyond—half that involve new molecular entities. These include potential treatments for oncology, urology and nephrology, immunology, and conditions of the central nervous system, while also advancing new areas of discovery research in areas such as ophthalmology and muscle diseases.
- Enzalutamide was first launched in 2012 for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC) and has recently been approved for metastatic chemo-naïve CRPC patients, as well as those with non-metastatic CRPC. Enzalutamide is the first and only oral treatment FDA-approved for both non-metastatic and metastatic CRPC.
- Gilteritinib is a tyrosine kinase inhibitor that was discovered through a research collaboration with Kotobuki Pharmaceutical Co., Ltd. Astellas has exclusive global rights to develop, manufacture, and potentially commercialize gilteritinib. It has demonstrated inhibitory activity against two common types of FLT3 mutations seen in approximately one-third of patients with Acute Myeloid Leukemia (AML). The FDA is currently evaluating Astellas’ New Drug Application (NDA) for gilteritinib with Priority Review for the treatment of adult patients who have relapsed or refractory AML with a FLT3 mutation. Currently, there are no FLT3-targeting agents approved for the treatment of relapsed or refractory FLT3 mutation-positive (FLT3mut+) AML.
- Mirabegron is the first and only Overactive Bladder treatment in its class that targets the β3 pathway. Mirabegron is sold in approximately 50 countries worldwide.
- Astellas cares about its employees and their families. That is why they believe supporting a culture of caring will continue to differentiate Astellas as an organization and employer of choice. The company’s rewards package offers exceptional health plan coverage, financial benefits, expanded caregiving services and resources through family care solutions, flexible work schedules, paid family care leave, paid volunteer time off, and much more.
- Astellas’ 2018 open enrollment introduced a new Astellas benefit called Best Doctors. Best Doctors gives Astellas medical plan members access to the top 5% of medical experts in each specialty area. Nearly, 50,000 independent expert physicians in 450 specialties are available to provide comprehensive voluntary second opinions or an expert review of complex diagnoses and treatments plan all at no cost to Astellas medical plan members.
- Astellas believes that total well-being is about more than just physical health. It includes financial health, too. Astellas offers a comprehensive Financial Wellness program that includes a wellness allowance, free financial planning, and student loan refinancing resources and financial assessment tools to help employees feel more in control of their finances today—and their financial plan for tomorrow.
- In 2017, the Astellas USA Foundation provided nearly $2 million, funding 25 grants to organizations that support the three Living SMART® pillars: Health & Wellbeing, STEM, and Disaster Relief. Highlights include: Providing the third consecutive year of support to the UN Foundation Shot@Life program; launching the Rural SPARK program in 26 rural Illinois schools through a $1 million grant to Project Lead The Way; and working with the Astellas corporation to send employee volunteers to aid Houston and Orlando hurricane relief efforts, one of only four companies to do so, as part of the Red Cross Disaster Responder Program.
- Astellas employees also volunteered more than 16,000 hours in the community in 2017—raising their total employee volunteerism hours to more than 110,000 hours since 2009.